久久久久一级片-国产69久久精品成人看-欧美日韩精品一区二区三区-日韩精品午夜

篩選
全部清除
發表時間
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
產品類型
研究領域
腫瘤
神經
代謝
內臟
mRNA疫苗
膀胱癌
細胞癌
肝臟
前列腺癌
細胞轉錄
乳腺癌
視網膜細胞癌
直腸癌
炎癥
阿茲海默癥
卵巢癌
甲狀腺癌
宮頸癌
急性髓系白血病
高血糖
糖尿病
冠狀病毒
胃癌
其他
結直腸癌
頭頸癌
腎炎
肝癌
肺癌
肺腺癌
鼻咽癌
胰腺癌
骨癌
減肥
哮喘
免疫
腎癌
當前位置:資源中心 > 客戶文獻
客戶文獻
共 233 內容
IF=12.658,Journal of Experimental & Clinical Cancer Research,中山大學附屬第一醫院,ARE-luc, HRE-luc , NF-κB-luc , FOXO-luc SMAD- luc,TCF-1-luc報告基因質粒
ALG3 contributes to stemness and radioresistance through regulating glycosylation of TGF-β receptor II in breast cancer
IF=13.933,Metabolism Clinical and Experimental,中國科學院大學,miRNA過表達AAV
MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice
IF=12.067,Cell Death & Differentiation,南京醫科大學基礎醫學院病理學系,永生化慢病毒
Epithelium-and endothelium-derived exosomes regulate the alveolar macrophages by targeting RGS1 mediated calcium signaling-dependent immune response
IF=15.254,BRAIN,浙江大學醫學院,干擾慢病毒
Bi-allelic loss of function variants in COX20 gene cause autosomal recessive sensory neuronopathy
IF=16.744,Chemical Engineering Journal,天津大學醫學工程與轉化醫學研究院,S蛋白假病毒
Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19
IF=17.521,Advanced Science,上海市新藥設計重點實驗室,過表達慢病毒
Multi‐Arm PEG/Peptidomimetic Conjugate Inhibitors of DR6/APP Interaction Block Hematogenous Tumor Cell Extravasation
IF=10.334,Pharmacological Research,中國科學院上海藥物研究所,過表達AAV
New PCSK9 inhibitor miR-552-3p reduces LDL-C via enhancing LDLR in high fat diet-fed mice
IF=11.6,Theranostics,中國藥科大學中藥學院,過表達質粒,sgRNA質粒
The role of GLS1-mediated glutaminolysis/2-HG/H3K4me3 and GSH/ROS signals in Th17 responses counteracted by PPARγ agonists
IF=38.102,Signal Transduction and Targeted Therapy,廣西國際納米抗體研究中心,過表達質粒
Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy
IF=31.791,Gut,復旦大學,siRNA合成
Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism
首頁 15 16 17 18 19 末頁
共 24 頁
跳轉
當前位置:資源中心 > 客戶文獻

客戶文獻
共 233 內容
IF=12.658,Journal of Experimental & Clinical Cancer Research,中山大學附屬第一醫院,ARE-luc, HRE-luc , NF-κB-luc , FOXO-luc SMAD- luc,TCF-1-luc報告基因質粒
ALG3 contributes to stemness and radioresistance through regulating glycosylation of TGF-β receptor II in breast cancer
IF=13.933,Metabolism Clinical and Experimental,中國科學院大學,miRNA過表達AAV
MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice
IF=12.067,Cell Death & Differentiation,南京醫科大學基礎醫學院病理學系,永生化慢病毒
Epithelium-and endothelium-derived exosomes regulate the alveolar macrophages by targeting RGS1 mediated calcium signaling-dependent immune response
IF=15.254,BRAIN,浙江大學醫學院,干擾慢病毒
Bi-allelic loss of function variants in COX20 gene cause autosomal recessive sensory neuronopathy
IF=16.744,Chemical Engineering Journal,天津大學醫學工程與轉化醫學研究院,S蛋白假病毒
Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19
IF=17.521,Advanced Science,上海市新藥設計重點實驗室,過表達慢病毒
Multi‐Arm PEG/Peptidomimetic Conjugate Inhibitors of DR6/APP Interaction Block Hematogenous Tumor Cell Extravasation
IF=10.334,Pharmacological Research,中國科學院上海藥物研究所,過表達AAV
New PCSK9 inhibitor miR-552-3p reduces LDL-C via enhancing LDLR in high fat diet-fed mice
IF=11.6,Theranostics,中國藥科大學中藥學院,過表達質粒,sgRNA質粒
The role of GLS1-mediated glutaminolysis/2-HG/H3K4me3 and GSH/ROS signals in Th17 responses counteracted by PPARγ agonists
IF=38.102,Signal Transduction and Targeted Therapy,廣西國際納米抗體研究中心,過表達質粒
Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy
IF=31.791,Gut,復旦大學,siRNA合成
Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism
MORE
篩選
全部清除
發表時間
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
產品類型
研究領域
腫瘤
神經
代謝
內臟
mRNA疫苗
膀胱癌
細胞癌
肝臟
前列腺癌
細胞轉錄
乳腺癌
視網膜細胞癌
直腸癌
炎癥
阿茲海默癥
卵巢癌
甲狀腺癌
宮頸癌
急性髓系白血病
高血糖
糖尿病
冠狀病毒
胃癌
其他
結直腸癌
頭頸癌
腎炎
肝癌
肺癌
肺腺癌
鼻咽癌
胰腺癌
骨癌
減肥
哮喘
免疫
腎癌
重置
確定
Tel: 400-627-9288
留言咨詢
重置
提交
客服
微信
電話
留言
留言咨詢
重置
提交